CAM
VNDA icon

ClariVest Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

ClariVest Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-66,968
Closed -$290K – 959
2023
Q3 		$290K Hold
66,968
– – 0.02% 366
2023
Q2 		$442K Buy
66,968
+24,481
+58% +$157K 0.02% 356
2023
Q1 		$288K Sell
42,487
-13
-0% -$91 0.01% 413
2022
Q4 		$314K Sell
42,500
-700
-2% -$6.82K 0.02% 412
2022
Q3 		$427K Buy
43,200
+13,800
+47% +$146K 0.02% 380
2022
Q2 		$320K Hold
29,400
– – 0.01% 425
2022
Q1 		$332K Sell
29,400
-4,037
-12% -$53.1K 0.01% 432
2021
Q4 		$525K Sell
33,437
-600
-2% -$10.5K 0.02% 428
2021
Q3 		$584K Sell
34,037
-100
-0.3% -$1.75K 0.02% 417
2021
Q2 		$735K Hold
34,137
– – 0.02% 357
2021
Q1 		$513K Sell
34,137
-27,555
-45% -$446K 0.02% 409
2020
Q4 		$809K Sell
61,692
-40,773
-40% -$491K 0.03% 299
2020
Q3 		$990K Sell
102,465
-42,193
-29% -$451K 0.03% 302
2020
Q2 		$1.66M Sell
144,658
-847
-0.6% -$9.59K 0.05% 260
2020
Q1 		$1.51M Buy
145,505
+27,040
+23% +$335K 0.05% 235
2019
Q4 		$1.94M Sell
118,465
-27,965
-19% -$423K 0.04% 251
2019
Q3 		$1.95M Buy
146,430
+32,800
+29% +$457K 0.04% 260
2019
Q2 		$1.6M Sell
113,630
-1,017
-0.9% -$16.2K 0.04% 271
2019
Q1 		$2.11M Buy
114,647
+75,519
+193% +$1.72M 0.04% 305
2018
Q4 		$1.02M Sell
39,128
-1,550
-4% -$36.4K 0.02% 391
2018
Q3 		$933K Hold
40,678
– – 0.02% 431
2018
Q2 		$775K Sell
40,678
-5,900
-13% -$98.7K 0.01% 473
2018
Q1 		$784K Buy
46,578
+579
+1% +$9.69K 0.01% 455
2017
Q4 		$698K Buy
45,999
+40,000
+667% +$594K 0.01% 459
2017
Q3 		$107K Buy
5,999
+232
+4% +$3.88K ﹤0.01% 536
2017
Q2 		$94K Hold
5,767
– – ﹤0.01% 551
2017
Q1 		$81K Buy
+5,767
New +$82.2K ﹤0.01% 575

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

ClariVest Asset Management's VNDA Position: Q4 2023 in Review

ClariVest Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 66,968 shares — an estimated $290K sold.

ClariVest Asset Management first reported a position in VNDA in Q1 2017 and held it in 27 quarters. The position peaked at $2.11M in Q1 2019. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

  • ClariVest Asset Management reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • ClariVest Asset Management sold 66,968 Vanda Pharmaceuticals shares in Q4 2023, an estimated $290K.
  • ClariVest Asset Management first reported a position in Vanda Pharmaceuticals in Q1 2017 and held it in 27 quarters.
  • ClariVest Asset Management's Vanda Pharmaceuticals position peaked at $2.11M in Q1 2019.
  • 157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on ClariVest Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.